Hypoglycosylated modified kallikrein 1 and its polyethylene glycol modification and their pharmaceutical applications
Hypoglycosylated KLK1 mutants with polyethylene glycol modification address stability and immunogenicity issues, offering improved therapeutic efficacy and reduced dosing frequency for conditions like acute ischemic stroke and chronic kidney disease.
Patent Information
- Application Number
- JP2024529618
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-16
- Filing Date
- 2022-11-16
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2042-11-16
AI Technical Summary
Existing KLK1 products face challenges with low biological stability, short half-life, repeated administration, and immunogenicity, along with uncertainties regarding the impact of glycosylation modifications on drug efficacy and safety.
Development of hypoglycosylated KLK1 mutants with reduced glycosylation modifications at specific sites, combined with polyethylene glycol modification to enhance stability, reduce immunogenicity, and improve pharmacokinetic properties.
The hypoglycosylated KLK1 mutants exhibit higher activity, improved stability, and reduced immunogenicity, allowing for less frequent dosing and enhanced therapeutic efficacy in treating conditions such as acute ischemic stroke, diabetic nephropathy, and chronic kidney disease.
Smart Images

Figure 2024542213000045 
Figure 2024542213000046 
Figure 2024542213000047
Abstract
Description
[Technical field]
[0001] The present invention relates to hypoglycosylated kallikrein 1 (KLK1) and its polyethylene glycol-modified derivatives and their applications in medicine, particularly to KLK1 with no or only a small amount of glycosylation modification in the NFS sequence, KLK1 mutants in which the NFS sequence of recombinant KLK1 has been mutated, and polyethylene glycol-modified derivatives of these KLK1 and their applications in medicine. [Background technology]
[0002] Kallikrein, also called kininogenase or kallidinogenase, is a type of serine protease and is divided into two types, plasma kallikrein (PK) and tissue kallikrein (TK), both of which exert very important physiological functions. Currently, human tissue kallikrein is thought to be composed of at least 15 members (KLK1-KLK15), of which tissue kallikrein 1 (KLK1) has been relatively well studied. KLK1 converts kininogen to kinin and acts on the corresponding receptor to exert a series of biological functions. Many studies have shown that KLK1 acts in the nervous system, circulatory system, respiratory system, diabetes, cancer, kidney disease, etc.
[0003] At present, there are two types of KLK1 products sold at home and abroad. One is pancreatic kallikrein 1 extracted from porcine pancreas, such as Changzhou Qianhong Pharmaceutical's Yikai. This type of KLK1 product is limited by the raw materials derived from animals. The other is KLK1 extracted from human urine, such as Guangdong Tianpu's Urinary Kallikrein Injection. Human urine is difficult to collect, has a low yield, has the risk of viral contamination, and has a Glu / Lys polymorphism at the 162nd amino acid position of urinary KLK1, so this type of KLK1 product poses great challenges in drug quality control. In addition to the aforementioned natural extract KLK1, there have been many research reports on recombinant human kallikrein 1. The most advanced of these is DiaMedica's DM199, which is currently undergoing phase 2 / 3 clinical studies for the treatment of stroke.
[0004] KLK1 is an enzyme with abundant glycosylation modifications, and the degree of glycosylation modification has a significant impact on the enzyme activity. N-glycosylation modification is the most notable type of glycosylation modification for glycoprotein drugs, in which sugar chains are attached through the free radical -NH2 of a specific asparagine in the nascent peptide chain. The triad sequence motif of the N-glycosylation modification site must be NXS or NXT, where N represents asparagine, S represents serine, T represents threonine, and X represents an amino acid other than proline. If the above conditions are not met, N-glycosylation modification will not occur in asparagine. Different N-glycosylation motifs are located at different positions in the tertiary structure of glycoproteins, and the structure of the glycoprotein determines which glycosyltransferase the glycosylation modification site binds to, resulting in different glycosylation modifications. In the prior art, there is no consensus on how different glycosylation degrees affect the efficacy and safety of KLK1. In Chinese Patent CN107058269A (Patent Document 1), porcine pancreatic kallikrein 1 was purified to separate and produce protein products with three degrees of glycosylation: highly glycosylated, medium glycosylated, and low glycosylated. Among them, the enzyme activity stability of low glycosylated porcine pancreatic kallikrein 1 was low. By removing this low glycosylated kallikrein 1 through the purification process, the biological activity of the product could be improved and side effects reduced. In Guangdong Tianpu's Patent CN101134952A (Patent Document 2), high molecular weight kallikrein 1 and low molecular weight kallikrein 1 were separated from the intermediate of urinary kallikrein 1 to obtain two types of components. Among them, a high molecular weight component was selected as the drug component. This single component high molecular weight human urinary kallikrein 1 had significantly fewer side effects than a mixture of human urinary kallikrein 1 containing high and low molecular weight kallikrein 1. Guangdong Tianpu has also attempted to express recombinant human kallikrein 1 using CHO, and the company's patent CN101134953A (Patent Document 4) discloses high molecular weight KLK1 containing three glycosylation modification sites. DiaMedica's patent US20130323222A (Patent Document 3) discloses that recombinant human kallikrein 1 was expressed and purified using CHO, and hyperglycosylated KLK1 and hypoglycosylated KLK1 were obtained, respectively. Although there was no significant difference in the in vivo activity of hyperglycosylated and hypoglycosylated kallikrein 1, a mixture of hyperglycosylated and hypoglycosylated kallikrein 1 in a 1:1 ratio was more active than a single hyperglycosylated KLK1 or a single hypoglycosylated KLK1.
[0005] Furthermore, even if the glycosylated modified KLK1 with the highest drug discovery potential is determined, how to control the glycosylation level of glycoproteins remains an important technical challenge in modern pharmaceutical industrial production. Usually, in order to obtain the desired glycosylated product to the maximum extent, extensive optimization must be carried out on the recombinant expression and purification conditions. For example, Chinese patent CN101134953A (Patent Document 4) expresses recombinant KLK1 in CHO, and paragraph
[0010] states that "the glycosylation degree of the expression product is increased by optimizing the culture conditions." Chinese Patent CN101092598A (Patent Document 5) uses Pichia yeast to express recombinant KLK1, and in the expression product, hyperglycosylated KLK1 has a molecular weight of 32,871.16 D, accounting for a small proportion, and hypoglycosylated KLK1 has a molecular weight of 28,975.79 D, accounting for a relatively high proportion. Although the molecular weights of hyperglycosylated KLK1 and hypoglycosylated KLK1 are close, the two were separated by three-stage purification.
[0006] Besides the challenges related to KLK1 glycosylation, KLK1 products have other challenges to overcome, including low biological stability, short half-life, the need for repeated administration, and recombinant KLK1 protein has a certain degree of immunogenicity. For example, DM199 is administered by intravenous infusion of KLK1 within 24 hours of stroke onset, followed by subcutaneous injection every 3 days within 22 days. Clinical trial results show that KLK1 can reduce stroke incidence and prevent stroke recurrence in high-risk groups. As a drug that improves cerebral collateral compensation, KLK1 requires long-term and multiple administrations to achieve therapeutic effects. While long-term administration is an important application method of KLK1, frequent administration may reduce patient compliance.
[0007] Polyethylene glycol (PEG) modification technology is a technique for chemically modifying proteins and polypeptides using a polyethylene glycol modifying agent. Currently, more than 10 types of PEG-modified protein drugs are commercially available. PEG-modified proteins can increase protein solubility, improve protein stability, extend in vivo half-life, and reduce immunogenicity. There are still few reports on PEGylated recombinant kallikrein 1 both in Japan and overseas. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] China Patent Application Publication No. 107058269 [Patent Document 2] China Patent Application Publication No. 101134952 [Patent Document 3] US Patent Publication No. 20130323222 [Patent Document 4] China Patent Application Publication No. 101134953 [Patent Document 5] China Patent Application Publication No. 101092598 Summary of the Invention [Problem to be solved by the invention]
[0009] The first technical problem that the present invention aims to solve is the selection of KLK1 glycosylation modification.The second technical problem that the present invention aims to solve is the problem that existing KLK1 products have low biological stability, short half-life, need for repeated administration, and recombinant KLK1 protein has a certain degree of immunogenicity. [Means for solving the problem]
[0010] The first technical problem that the present invention aims to solve is the selection of KLK1 glycosylation modification. As mentioned in the background art, the prior art has no consensus on how different glycosylation degrees affect the efficacy and safety of KLK1. Even if the most druggable glycosylation-modified KLK1 is determined, extensive optimization must be carried out on recombinant expression and purification conditions to control the glycosylation level of glycoproteins to maximize the desired glycosylation product.
[0011] Through characterization, the applicant of the present application found that human kallikrein 1 (hKLK1) has three glycosylation sites, which are N78 (N in the NMS sequence), N84 (N in the NHT sequence), and N141 (N in the NFS sequence). Among them, hyperglycosylated KLK1 has glycosylation at all three sites, while hypoglycosylated KLK1 has glycosylation at two sites, N78 and N84, and no or only a small amount of glycosylation at N141. Furthermore, the applicant compared the biological activities of hyperglycosylated KLK1 and hypoglycosylated KLK1 and unexpectedly found that the activity of hypoglycosylated KLK1 was much higher than that of hyperglycosylated KLK1. Furthermore, in order to obtain hypoglycosylated KLK1, the applicant did not optimize recombinant expression conditions or purification conditions as in conventional methods, but instead mutated one or more amino acids in the NFS sequence motif to avoid forming an N-glycosylation motif based on the research on high- and low-glycosylated KLK1, thereby creating a mutant, which resulted in a more uniform product and a higher production of hypoglycosylated hKLK1.The applicant then compared the above-mentioned hypoglycosylated KLK1 mutant with the unmutated hypoglycosylated KLK1 and made the surprising discovery that the mutant was superior in terms of enzymatic properties, activity, etc.
[0012] There are many natural variants (homologs) of hKLK1, such as those registered under Genbank accession numbers AAA59455.1, NP002248.1, AAA36136.1, AAP35917, AAU12569, etc. In terms of composition, the natural variants of hKLK1 have the same number of amino acids, differing only by a few amino acids (as shown in the table below), and are highly homologous, with essentially similar in vivo and in vitro activities. The inventors have also discovered that the glycosylation modification sites of these natural variants are the same, all located at N78, N84, and N141, and the triad sequence motifs of the N-glycosylation modification sites are also the same, all of which are NMS, NHT, and NFS.
[0013] [Table 1]
[0014] The present invention uses hKLK1 registered under Genbank accession number AAA59455.1 as a basis, and mutates one or more amino acids in the NFS sequence motif to obtain KLK1 (hypoglycosylated KLK1) containing only two N-glycosylation modification sites. As described above, the amino acid composition and glycosylation modification sites of natural variants of hKLK1 are highly consistent, and the corresponding positions (i.e., one or more amino acids in the NFS sequence motif) of other natural variants of hKLK1 can be mutated to achieve the same technical effect. That is, the product is more uniform, the yield of hypoglycosylated hKLK1 is higher, and the target product with higher activity can be obtained.
[0015] In addition, the present inventors have found that KLK1 from other primates, such as NCBI Reference Sequence: XP_004061305.1 (gorilla), XP_003916022.1 (Anubis baboon), XP_003813685.1 (bonobo), XP_002829668.3 (Sumatran orangutan), XP_032024960.1 (hoolock gibbon), also contains three N-glycosylation modification sites similar to hKLK1, and the triad sequence motifs of the N-glycosylation modification sites are the same, all of which are NMS, NHT, and NFS. The corresponding sites of the natural amino acids of KLK1 from other primates (i.e., one or more amino acids in the NFS sequence motif) can also be mutated to achieve the same technical effect. This results in a more homogeneous product, a higher yield of underglycosylated hKLK1, and a more active target product.
[0016] Based on the above findings, the present invention provides a type of hypoglycosylated KLK1 or its derivatives. The KLK1 is a primate KLK1, which includes N-glycosylation modifications at the NMS, NHT, and NFS sequences of natural KLK1, in which the asparagine at NFS has no glycosylation modification or only a small amount of glycosylation modification. The small amount of glycosylation modification or hypoglycosylation modification means that the glycosylation rate of asparagine at NFS is ≦10%, ≦9%, ≦8%, ≦7%, ≦6%, ≦5%, ≦4%, ≦3%, ≦2%, ≦1%, ≦0.5%, or ≦0.1%. In a specific embodiment, the hypoglycosylated KLK1 has 96.39% of asparagine at NFS not glycosylated, and only less than 4% of asparagine at NFS is glycosylated. This hypoglycosylated KLK1 has higher activity compared to KLK1 with hyperglycosylation modifications in the NFS.
[0017] Furthermore, the present invention provides a recombinant KLK1 mutant or its derivative. The KLK1 is a primate KLK1, and the recombinant KLK1 or its derivative does not include KLK1 with N-glycosylation modification at only two sites, and does not include KLK1 with N-glycosylation modification at three sites. The primate may be a human or a non-human primate such as a gorilla, an Anubis baboon, a bonobo, a Sumatran orangutan, or a hoolock gibbon. It is also possible.
[0018] Preferably, said recombinant KLK1 mutant or derivative thereof retains the N-glycosylation modifications at NMS, NHT of native KLK1, but does not contain the N-glycosylation modification at NFS of native KLK1.
[0019] Preferably, N (asparagine) of NFS in the KLK1 amino acid sequence is mutated to any amino acid other than asparagine. That is, asparagine at position 141 is mutated to any other amino acid, and 0, 1 or 2 amino acids of F, S of NFS are mutated to any other amino acid. As a result, the mutant does not form an N-glycosylation motif at the corresponding position, so that no glycosylation modification occurs at position 141. Compared with the unmutated hypoglycosylated KLK1, all of the different mutants have more uniform products, higher yields of hypoglycosylated KLK1, and better activity of the products. Preferably, the F (phenylalanine) of NFS in the KLK1 amino acid sequence is mutated to proline. That is, the 142nd phenylalanine is mutated to proline, and 0, 1 or 2 amino acids of N and S of NFS are mutated to any other amino acid. As a result, the mutant does not form an N-glycosylation motif at the corresponding position, so that no glycosylation modification occurs at position 141. Similarly, all of the mutants have more uniform products, higher yields of hypoglycosylated KLK1, and better product activity compared to the unmutated hypoglycosylated KLK1 product.
[0020] Preferably, the S (serine) of NFS in the KLK1 amino acid sequence is mutated to any amino acid other than serine or threonine. That is, the 143rd serine is mutated to any amino acid other than serine or threonine, and 0, 1 or 2 amino acids of N and F of NFS are mutated to any other amino acid. As a result, the mutant does not form an N-glycosylation motif at the corresponding position, so that no glycosylation modification occurs at position 141. Similarly, compared with the unmutated hypoglycosylated KLK1, all of the mutants have more uniform products, higher yields of hypoglycosylated KLK1, and better product activity.
[0021] In a specific embodiment, asparagine is mutated to four different amino acids, such as polar neutral amino acids (e.g., glutamine (Gln)), acidic amino acids (e.g., aspartic acid (Asp)), basic amino acids (e.g., arginine (Arg)), and aliphatic amino acids (e.g., alanine (Ala)). As a result, the mutants do not form N-glycosylation motifs in NFS, so that no glycosylation modification occurs there. Compared with the unmutated hypoglycosylated KLK1, all of the different mutants have more uniform products, higher yields of hypoglycosylated KLK1, and better product activity.
[0022] Preferably, the KLK1 is hKLK1, and the amino acid sequence of the native hKLK1 is, for example, a sequence registered under GenBank accession numbers AAA59455.1, NP002248.1, AAA36136.1, AAP35917, AAU12569, etc.
[0023] Preferably, the amino acid sequence of the KLK1 mutant is SEQ ID No:3, SEQ The sequence is represented by SEQ ID No:4, SEQ ID No:5, or SEQ ID No:6.
[0024] The present invention also provides a composition comprising the underglycosylated KLK1.
[0025] KLK1 converts kininogen into kinin and exerts a series of biological effects by acting on the corresponding receptors. KLK1 is involved in the nervous system, circulatory system, respiratory system, diabetes, cancer, kidney disease, etc. Many studies have shown that KLK1 acts in the treatment of acute ischemic stroke. Currently available KLK1 has been approved for use in the treatment of microcirculatory disorders, such as diabetic nephropathy, peripheral neuropathy, retinopathy, fundus disease, and hypertension, and can also be used as an adjunct to mild to moderate acute thrombotic cerebral infarction. Indications in clinical trials include IgA nephritis and chronic kidney disease. The KLK1 mutant of the present invention has only a few amino acids mutated compared to native KLK1. In specific examples, it has been confirmed that the mutants all exhibit activity when acting on the same substrate in vitro, and it has also been demonstrated that they exhibit activity in improving cerebral infarction symptoms in an MCAO cerebral ischemia-reperfusion model in vivo. Those skilled in the art can reasonably expect that the recombinant KLK1 mutant and its composition of the present invention are effective in treating and preventing acute ischemic stroke, peripheral neuropathy, retinopathy, fundus disease, hypertension, diabetic nephropathy, IgA nephritis, and chronic kidney disease, as well as in improving prognosis and preventing recurrence, in the same way as native KLK1.
[0026] The second technical problem that the present invention aims to solve is the problem of existing KLK1 products, such as low biological stability, short half-life, need for repeated administration, and certain degree of immunogenicity of recombinant KLK1 protein. The present invention provides KLK1 modified by a polyethylene glycol modifier, which significantly enhances protein stability, reduces immunogenicity, improves the in vivo pharmacokinetic properties of the protein, and maximizes protein activity.
[0027] Preferably, the PEG-modified KLK1 is the underglycosylated KLK1.
[0028] Preferably, the KLK1 is a recombinant KLK1 or a derivative thereof having N-glycosylation modifications at two sites, and does not include KLK1 having N-glycosylation modifications at three sites.
[0029] Preferably, the polyethylene glycol modifying agent forms a covalent bond to the N-terminus or free amino group of lysine of the KLK1 protein, and has a general structural formula as shown in formula (1-1) or formula (1-2), in which R represents KLK1. In formula (1-1), n is an integer of 335 to 455, and in formula (1-2), n is an integer of 105 to 225, and m is an integer of 1 to 8.
[0030] [ka] (1‐1)
[0031] [ka] (1‐2)
[0032] Preferably, the polyethylene glycol modifying agent is a straight chain having a molecular weight of 5 kDa to 10 kDa. It is a linear polyethylene glycol succinimide propionate and has the general structural formula shown in formula (2). In formula (2), n is an integer of 105 to 225.
[0033] [ka] (2)
[0034] Preferably, the polyethylene glycol modifying agent is a branched polyethylene glycol propionaldehyde having a molecular weight of 30 kDa to 40 kDa, and has a general structural formula as shown in formula (3).
[0035] [ka] (3)
[0036] The present invention provides a method for producing the pegylated KLK1, comprising the steps of: Step 1: Buffer replacement Replace the KLK1 to be modified with the modification buffer by methods such as desalting with a chromatography column, dialysis, concentration / dilution, and cross-flow ultrafiltration; Step 2: Modification reaction and purification of the modified product The KLK1 solution collected in step 1 is reacted with a PEG modifier, and after the reaction is complete, it is purified by ion exchange chromatography.
[0037] The present invention also provides a composition comprising the pegylated KLK1.
[0038] The present invention also provides applications of the polyethylene glycol-modified KLK1 in the treatment, prevention, prognosis improvement, and recurrence prevention of acute ischemic stroke, peripheral neuropathy, retinopathy, ocular fundus disease, hypertension, diabetic nephropathy, IgA nephritis, and chronic kidney disease. Effect of the Invention
[0039] Compared with the prior art, the present invention has the following advantages: First, the underglycosylated KLK1 of the present invention has clear advantages. First, the underglycosylated KLK1 of the present invention has no or only a small amount of glycosylation modification in NFS and has higher activity compared to the hyperglycosylated KLK1.
[0040] Secondly, the recombinant KLK1 mutant of the present invention has an additional advantage.
[0041] The recombinant KLK1 mutant of the present invention has N-glycosylation modifications compared to the native KLK1. In terms of the manufacturing process, the recombinant hKLK1 mutant of the present invention The purification process requires only the collection of the main peak, making the purification process simpler. In terms of quality, the present invention does not require separation of hyperglycosylated KLK1 and hypoglycosylated KLK1, so the target product obtained is more uniform, the quality control is easier, and the yield is higher. In terms of activity and efficacy, the applicant has made a surprising discovery by comparing the hypoglycosylated KLK1 mutant of the present invention with the unmutated hypoglycosylated KLK1, that the mutant is superior in terms of enzymatic properties, activity, etc.
[0042] Secondly, the present invention uses PEGylation technology to develop a PEGylated recombinant hKLK1 with long-acting properties, quality controllability, low immunogenicity and high biological activity. And through efficacy and pharmacokinetic studies, the advantages of safety and long-acting properties of the PEGylated drug are fully explored, which reduces the frequency of administration and improves patient compliance, and realizes the application of the drug of the present invention in the whole disease process, covering the stages of prevention, treatment, prognosis recovery, recurrence prevention and other stages for diseases such as acute ischemic stroke, peripheral neuropathy, retinopathy, ocular fundus disease, hypertension, diabetic nephropathy, IgA nephritis, and chronic kidney disease. [Brief description of the drawings]
[0043] [Figure 1] FIG. 1 shows the molecular design of recombinant hKLK1 and mutants. [Diagram 2] Figure 1: pZHK2.0 expression vector. [Diagram 3] Figure 1 shows chromatograms of hydrophobic chromatography elution peaks from the fermentation supernatant of wild-type recombinant hKLK1 expressed in CHO, with the arrows indicating the separated hyperglycosylated (left) and hypoglycosylated (right) products. [Figure 4] SDS-PAGE electrophoresis of hyperglycosylated and hypoglycosylated proteins obtained by purification and separation of wild-type hKLK1 expressed in CHO cells. Lane M is a protein marker, lane 1 is hyperglycosylated hKLK1, and lane 2 is hypoglycosylated hKLK1. [Diagram 5]1 shows a chromatogram of the hydrophobic chromatography elution peak of the fermentation supernatant of hKLK1X1 (recombinant hKLK1 mutant) expressed in CHO, with the arrow indicating the isolated single underglycosylated product. [Figure 6] 1 shows an SDS-PAGE electrophoresis pattern of the hypoglycosylated protein obtained by purification and separation of hKLK1X1 (recombinant hKLK1 mutant) expressed in CHO, where lane M is a protein marker and lane 1 is the hypoglycosylated hKLK1 mutant. [Figure 7] SDS-PAGE electrophoretogram of wild-type recombinant hKLK1 expressed in CHO cells when hyper- and hypo-glycosylated proteins were not separated. Lane M is a protein marker, and lane 1 is wild-type recombinant hKLK1 with a mixture of hyper- and hypo-glycosylated proteins. [Figure 8] FIG. 1 shows sequence coverage after trypsin enzymatic digestion of hyperglycosylated hKLK1 samples. [Figure 9] FIG. 1 shows sequence coverage after trypsin enzymatic digestion of underglycosylated hKLK1 samples. [Figure 10] FIG. 1 shows TIC chromatograms after trypsin enzymatic digestion of three batches of hyperglycosylated hKLK1 samples. [Figure 11] FIG. 1 shows TIC chromatograms after trypsin enzymatic digestion of three batches of underglycosylated hKLK1 samples. [Figure 12] FIG. 1 shows sequence coverage after trypsin enzymatic digestion of hKLK1X1 samples. [Figure 13] FIG. 1 shows the results of measuring anti-drug antibodies in animals administered PEG-hKLK1 (underglycosylated). [Figure 14] FIG. 1 shows the results of measuring anti-drug antibodies in animals administered PEG-hKLK1 (hyperglycosylated). [Figure 15] 1 is a graph showing the effect of the test substance of Example 10 on symptoms of neurological deficit. [Figure 16]1 is a graph showing the effect of the test substance of Example 10 on cerebral infarction area. [Figure 17] FIG. 13 shows photographs of brain sections from a model group and a sham-operated group in the animal experiment of Example 10. [Figure 18] FIG. 13 shows photographs of brain sections from the Urinary Kallikrein group and the Injectable Pancreatic Kallikrein 1 group in the animal experiment of Example 10. [Figure 19] 1 is a graph showing the effect of the test substance of Example 11 on neurological deficit symptoms. [Figure 20] 1 is a graph showing the effect of the test substance of Example 11 on cerebral infarction area. [Figure 21] FIG. 13 shows photographs of brain sections from a model group and a sham-operated group in the animal experiment of Example 11. [Figure 22] FIG. 13 is a photograph of a brain section from the administration group in the animal experiment of Example 11. [Diagram 23] 1 is a graph showing the effect of the test article of Example 12 on neurological deficit symptoms. [Figure 24] 1 is a graph showing the effect of the test substance of Example 12 on cerebral infarction area. [Diagram 25] FIG. 13 shows photographs of brain slices from a model group, a sham operation group, and a positive drug group in the animal experiment of Example 12. [Figure 26] FIG. 13 shows photographs of brain sections from groups administered with hKLK1 modified with different PEGs in the animal experiment of Example 12. [Figure 27] 1 is a graph showing the effect of the test article of Example 13 on neurological deficit symptoms. [Figure 28] 1 is a graph showing the effect of the test substance of Example 13 on cerebral infarction area. [Figure 29] FIG. 13 shows photographs of brain sections from a model group and a sham-operated group in the animal experiment of Example 13. [Diagram 30] FIG. 13 shows photographs of brain sections from groups administered with hKLK1 mutants modified with different PEGs in the animal experiment of Example 13. [Diagram 31] 1 is a graph showing the effect of the test substance of Example 14 on neurological deficit symptoms. [Diagram 32] 1 is a graph showing the effect of the test substance of Example 14 on cerebral infarction area. [Diagram 33] FIG. 13 shows photographs of brain sections from a model group and a sham-operated group in the animal experiment of Example 14. [Diagram 34] FIG. 13 shows photographs of brain sections from the administration group in the animal experiment of Example 14. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0044] Unless otherwise specified, technical terms or abbreviations in the present invention have the following meanings: Kallikrein 1: Specifically refers to tissue kallikrein 1 (KLK1).
[0045] hKLK1: refers to unmutated human tissue kallikrein 1 whose sequence is identical to native human tissue kallikrein 1, and includes various homologues of human KLK1, including, but not limited to, KLK1 registered under Genbank accession numbers AAA59455.1, NP002248.1, AAA36136.1, AAP35917, AAU12569, etc.
[0046] The three glycosylation modification sites of KLK1, N78, N84 and N141, refer to the asparagine at positions 78, 84 and 141 of the KLK1 amino acid sequence, respectively, and the corresponding N-glycosylation triad sequence motifs are NMS, NHT and NFS, respectively. N stands for asparagine, M stands for methionine, S stands for serine, H stands for histidine, T stands for threonine and F stands for phenylalanine.
[0047] Hyperglycosylated hKLK1: Unmutated hKLK1 that is hyperglycosylated, i.e., there are many glycosylation modifications at the glycosylation sites N78, N84, and N141.
[0048] Hypoglycosylated hKLK1: Unmutated hKLK1 with hypoglycosylation. In other words, there are many glycosylation modifications at both N78 and N84. However, at the glycosylation site N141, no or only a small amount of glycosylation occurred.
[0049] PEG-hKLK1 (hyperglycosylated): hyperglycosylated hKLK1 modified with polyethylene glycol. The hyperglycosylated hKLK1 refers to hKLK1 having the unmutated hyperglycosylation modification.
[0050] PEG-hKLK1 (hypoglycosylated): Hypoglycosylated hKLK1 modified with polyethylene glycol. The hypoglycosylated hKLK1 refers to hKLK1 having the unmodified hypoglycosylation modification.
[0051] hKLK1X: a mutant form of hKLK1. hKLK1X1, hKLK1X2, hKLK1X3, and hKLK1X4 each represent a different mutant form.
[0052] PEG-hKLK1X: hKLK1 mutant modified by polyethylene glycol.
[0053] KLK1 derivatives: Including the full-length KLK1 mutant protein of the present invention, also include portions of the KLK1 mutant protein of the present invention, or proteins obtained by further mutation based on the KLK1 mutant of the present invention, fusion proteins (including but not limited to albumin fusion, Fc fusion, etc.), and modified forms modified in various ways (excluding polyethylene glycol modified forms).
[0054] Polyethylene glycol: Abbreviated as PEG, it is usually formed by polymerization of ethylene oxide and is available in branched, linear and multi-armed forms. Generally, those with a molecular weight of 20,000 or less are called PEG, and those with a higher molecular weight are called PEO. Ordinary polyethylene glycol has hydroxyl groups at both ends, and blocking one end with a methyl group results in methoxy polyethylene glycol (mPEG).
[0055] Polyethylene glycol modifier: abbreviated as PEG modifier, refers to a polyethylene glycol derivative with functional groups, which is an activated polyethylene glycol used to modify protein and polypeptide drugs. The polyethylene glycol modifier used in the present invention is purchased from Jiangsu Zhonghong Bioengineering Drug Discovery Research Institute Co., Ltd. or Beijing Keykai Technology Co., Ltd. The actual molecular weight of a PEG modifier of a specific molecular weight may be 90%-110% of the indicated value. For example, the molecular weight of PEG5K may be 4.5kDa-5.5kDa.
[0056] PEG5K used in the examples specifically refers to M-SPA-5K, which is a linear methoxy polyethylene glycol succinimidyl propionate having a molecular weight of about 5 kDa and a structural formula as shown in formula (1), where n is an integer of 105 to 110.
[0057] [ka] (1)
[0058] PEG10K used in the examples specifically refers to M-SPA-10K, which is a linear methoxy polyethylene glycol succinimidyl propionate having a molecular weight of about 10 kDa and a structural formula as shown in formula (1), where n is an integer of 220 to 225.
[0059] PEG30K used in the examples specifically refers to Y-PALD-30K, which is a branched polyethylene glycol propionaldehyde with a molecular weight of about 30 kDa and has the structural formula shown in formula (2), where m is an integer of 335 to 340.
[0060] [ka] (2)
[0061] PEG40K used in the examples specifically refers to Y-PALD-40K, which is a branched polyethylene glycol propionaldehyde having a molecular weight of about 40 kDa and a structural formula as shown in formula (2), where m is an integer of 450 to 455. EXAMPLES
[0062] Example 1 Gene design, expression vector construction, expression, and purification of recombinant human kallikrein 1 (hKLK1) (1) Gene design and expression vector construction Based on the information of the hKLK1 sequence published in GenBank (GenBank: AAA59455.1), codon optimization was performed to obtain the amino acid sequence of the mature product (SEQ ID NO: 1). The cDNA sequence of hKLK1 (SEQ ID No:1) and the cDNA sequence of hKLK1 including the signal peptide and propeptide (SEQ ID No:2) were determined. The recombinant hKLK1 gene (SEQ ID No:2) was synthesized with an AvrII restriction site sequence added in front of it and a BstZ17I restriction site sequence added at the end of the sequence. The synthesized gene was constructed into pUC57 plasmid, and the resulting long-term storage plasmid was named pUC57-hKLK1 plasmid. The hKLK1 gene was amplified from the pUC57-hKLK1 plasmid using primers. The PCR product was recovered by 1% agarose electrophoresis, and the target gene PCR recovered product (Figure 1) and the pZHK2.0 vector (Figure 2) were double-digested with AvrII and BstZ17I, and the digested target gene was ligated into the pZHK2.0 vector using T4 ligase, and then transformed into Top10 competent cells, spread on a LB plate with kanamycin resistance, and cultured at 37°C overnight. The next day, positive clones were screened, sequenced, and compared, and were completely consistent with the expected sequence. Thus, the pZHK2.0-hKLK1 expression vector was constructed.
[0063] (2) Stable expression The plasmid constructed above was linearized by overnight enzyme digestion with NruI (R0192S, purchased from NEB) and introduced into CHO-S cells by electroporation, after which selection pressure was applied and screening was performed to obtain a stable cell line. The CHO stable cell line expressing high levels of recombinant hKLK1 was inoculated into Dynamis medium (A2617501, purchased from Thermo Fisher) and cultured at 37°C, 8% CO2, 130 rpm in a fed-batch manner. The culture medium was harvested after 2 weeks of culture.
[0064] (3) Purification 1. Pretreatment of culture medium The above culture fluid containing recombinant hKLK1 was collected, centrifuged at 6000 rpm for 15 min to remove cells, concentrated by ultrafiltration, and filtered through a 0.22 μm membrane to remove cell debris. 1.5 M (NH4)2SO4 was added and stirred at room temperature for 3 days to activate the culture fluid. The activated culture fluid was clarified by filtering through a 0.45 μm microfiltration membrane.
[0065] 2. Hydrophobic chromatography First, the column was equilibrated with buffer (20 mM Tris-HCl, 1.5 M ammonium sulfate, pH = 8.0) until the baseline was equilibrated. The pretreated supernatant was then passed through medium POROS Benzyl (A32563, purchased from Thermo Fisher) to capture recombinant hKLK1 from the medium. Gradient elution was then performed with 20 mM Tris-HCl, pH = 8.0, and two peaks separated by hydrophobicity were clearly observed. Each elution peak was collected, and recombinant hKLK1 proteins with different glycosylation modifications were thus separated. The chromatogram of the elution peaks is shown in Figure 3.
[0066] 3. Anion exchange The elution peak containing the recombinant hKLK1 protein collected in step 2 was ultrafiltered with a 10 kDa ultrafiltration membrane using 20 mM Tris-HCl, pH = 8.0 buffer until the conductivity was 10-15 ms / cm. The column was equilibrated with buffer (20 mM Tris-HCl, 100 mM NaCl, pH = 8.0) until the baseline was equilibrated. The ultrafiltered supernatant was then passed through a Medium Q FF (17515601, purchased from GE), and finally, the column was isocratically eluted with elution buffer (20 mM Tris-HCl, 1 M NaCl, pH = 8.0) to collect the main elution peak.
[0067] 4. Cation exchange Ultrafiltration was performed on the samples from step 3 to exchange the samples into 10 mM NaAc-HAc, 50 mM NaCl, pH=3.5-3.7. Medium SP FF (17072904, purchased from GE) was used to perform high purification on the recombinant hKLK1 of different molecular weights collected in the previous step. The equilibration buffer was 10 mM NaAc-HAc, 50 mM NaCl, pH=3.7, and the elution buffer was 50 mM Tris-HCl, 1 M NaCl, pH=8.0.
[0068] The purity of the purified samples was analyzed by SDS-PAGE gel electrophoresis. The results showed that the molecular weight of hyperglycosylated hKLK1 protein was slightly higher than that of hypoglycosylated hKLK1 protein, as shown in the SDS-PAGE gel electrophoresis pattern. The results are shown in Figure 4.
[0069] Example 2 Three batches of continuous production and quality characterization of recombinant human kallikrein 1 (hKLK1) Three batches of high-density continuous culture of wild-type recombinant hKLK1 were carried out in a 7L stirred reactor. The initial culture conditions were as follows: rotation speed 100 rpm, dissolved oxygen 40%, temperature 37°C, pH value 7.0, and basal medium Dynamis AGT Medium (purchased from Thermo Fisher Scientific). The seed suspension was harvested and inoculated into the bioreactor at a density of 5 x 10e5 cell / mL. On the third day, the temperature was adjusted to 33°C, and the feed medium (the feed medium was EfficientFeed C+AGT supplement purchased from Thermo Fisher Scientific) and glucose were separately supplemented to maintain the sugar content of the culture solution at not less than 2g / L. When the cell viability was below 90%, the culture solution was collected and purified by the purification process described in Example 1. As a result, three batches each of hyperglycosylated and hypoglycosylated recombinant hKLK1 were obtained.
[0070] Protein quality characterization was performed on these samples, including yield, SEC-HPLC purity, and LC / MS (Thermo Q Exactive) analysis of N / C-terminal amino acid sequences, peptide mapping, glycosylation site, and glycosylation modification. The results are summarized as follows:
[0071] [Table 2]
[0072] The analytical results shown in the above table show that the purity of the isolated hyperglycosylated recombinant hKLK1 and hypoglycosylated recombinant hKLK1 all reached 97% or more, and there was a difference in the molecular weight of the hyperglycosylated protein and the hypoglycosylated protein. The amino acid sequence coverage of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 was measured based on trypsin enzyme digestion, and the hypoglycosylated hKLK1 achieved 100% coverage, and the hyperglycosylated hKLK1 partially achieved 100% coverage, but some products had missing sequences at the N-terminus (Figures 8 and 9). The N / C-terminal sequence of hypoglycosylated hKLK1 was consistent with the theoretical sequence (Tables 6-8), and the peptide map characteristics of the three batches were consistent (Figure 11). However, in the 3-batch continuous production process, the N-terminal sequence of some protein components in the 2nd batch of the hyperglycosylated protein did not match the theoretical sequence, resulting in sequence deletions (Tables 3-5). And the peptide map of the 2nd batch did not match those of the 1st and 3rd batches (Figure 10). This suggests that the hyperglycosylated recombinant hKLK1 molecule may have stability defects. This will introduce great risks into the drug production process. In addition, the separation and purification process of hyperglycosylated and hypoglycosylated products is also relatively complicated, and due to the instability of the process, it will also be difficult to control the glycosylation level of the purified products in different batches.
[0073] [Table 3]
[0074] [Table 4]
[0075] [Table 5]
[0076] [Table 6]
[0077] [Table 7]
[0078] [Table 8]
[0079] [Table 9]
[0080] Furthermore, the analysis of glycosylation sites of recombinant hKLK1 showed that all recombinant hypoglycosylated hKLK1 had glycosylation modifications at N78 and N84, and almost no glycosylation modifications at N141 (96.39%). Only a small amount of hKLK1 had glycosylation modifications at N141 (less than 4%) (Table 9). Meanwhile, hyperglycosylated hKLK1 contained three N-glycosylation sites (N78, N84, and N141), with a wide variety of glycosylation modifications and a complex variety of glycoforms.
[0081] The elution peaks of the hyperglycosylated and hypoglycosylated proteins obtained by hydrophobic chromatography in Example 1 were combined, and the subsequent anion exchange purification and cation exchange purification were similarly performed to obtain a recombinant hKLK1 protein containing a mixture of hyperglycosylated and hypoglycosylated proteins. The purity of the purified sample was analyzed by SDS-PAGE gel electrophoresis, and the results are shown in Figure 7. The results showed that the hyperglycosylated and hypoglycosylated proteins formed diffuse bands, and a component with a larger molecular weight was present above the hyperglycosylated protein. As shown in Figure 3, the separation degree of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 from unmutated recombinant hKLK1 by hydrophobic purification was poor, and it was difficult to completely separate hyperglycosylated hKLK1 and hypoglycosylated hKLK1. In summary, the raw protein of unmutated hKLK1 contains a mixture of hyperglycosylated and hypoglycosylated hKLK1 with different molecular weights, and has heterogeneous and complex glycosylation modification degrees at N141, which poses great challenges for the quality control of recombinant hKLK1.
[0082] Furthermore, when the biological activities of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 were compared (Example 6), it was surprisingly found that the activity of hypoglycosylated hKLK1 was much higher than that of hyperglycosylated hKLK1.
[0083] Example 3. Design, expression vector construction, expression, and purification of recombinant human kallikrein 1 mutant (hKLK1X) Furthermore, in order to obtain hypoglycosylated hKLK1, the applicant of the present invention did not focus on optimizing the expression and purification conditions of recombinant hKLK1 as in the conventional method, but instead mutated one or more amino acids in the NFS sequence motif based on the above-mentioned research on high- and low-glycosylated hKLK1, so that glycosylation modification did not occur at the corresponding positions. This resulted in a mutant with a more uniform product and a higher yield of hypoglycosylated hKLK1. What's more, subsequent experiments showed that the hypoglycosylated mutant had further advantages in terms of enzymatic properties, activity, etc., compared to the unmutated hypoglycosylated hKLK1.
[0084] In the mutants listed in this example, N (i.e., N141) in the NFS sequence motif was mutated, and F and S in the NFS sequence motif were not mutated. However, these examples are for illustrative purposes only and do not limit the scope of the present invention. Any of the following methods can modify the original NFS sequence to prevent the formation of an N-glycosylation motif, thereby preventing glycosylation modification at N141. For example, mutating amino acid N (i.e., N141) in NFS and mutating 0, 1, or 2 amino acids in F and S to any other amino acids; mutating F (i.e., F142) in NFS to proline and mutating 0, 1, or 2 amino acids in N and S to any other amino acids; or mutating S (i.e., S143) in NFS to any amino acid except threonine and mutating 0, 1, or 2 amino acids in N and F to any other amino acids. The above method achieves a more homogeneous product and a higher yield of underglycosylated hKLK1, while the obtained mutant has additional advantages in enzymatic properties and activity compared to the unmutated form, which may be related to the absence of glycosylation modification in the original NFS sequence.
[0085] In addition, this embodiment lists mutants based on the hKLK1 sequence registered in Genbank under the accession number AAA59455.1, but this is for illustrative purposes only and does not limit the scope of the present invention. Although the amino acid composition and glycosylation modification site of other known natural variants of hKLK1 are highly identical, the same technical effect can be achieved by mutating the corresponding positions of other natural variants of hKLK1 (i.e., one or more amino acids in the NFS sequence motif). That is, the product is more uniform, the yield of low glycosylated hKLK1 is higher, and the target product has better activity. All KLK1s of other primates contain three types of N-glycosylation modification sites like hKLK1, and the triad sequence motif is the same, all of which are NMS, NHT, and NFS. The same technical effect can be achieved by mutating the corresponding positions of the natural amino acid sequences of other primate KLK1 (i.e., one or more amino acids in the NFS sequence motif). That is, the product is more homogeneous, the yield of underglycosylated hKLK1 is higher, and the desired product with better activity can be obtained.
[0086] The specific mutation patterns exemplified in this example are as follows: Site-directed mutagenesis was performed on the glycosylation modification site N141, and asparagine was mutated to four different amino acids, namely polar neutral amino acid glutamine (Gln), acidic amino acid aspartic acid (Asp), basic amino acid arginine (Arg), and aliphatic amino acid alanine (Ala), and the resulting hKLK1 mutants are named hKLK1X1 (SEQ ID No: 3), hKLK1X2 (SEQ ID No: 4), hKLK1X3 (SEQ ID No: 5), and hKLK1X4 (SEQ ID No: 6), respectively. Each mutant was prepared according to the preparation method of Example 1.
[0087] The above-mentioned recombinant hKLK1 mutants were purified by the three-step purification method in Example 1. In the hydrophobic purification chromatograms of the mutants, only one main elution peak due to hydrophobic elution appeared. Taking hKLK1X1 as an example, its hydrophobic chromatography elution chromatogram shown in FIG. 5 shows that the product after mutation is more homogeneous. Since the separation degree of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 during the purification process of unmutated recombinant hKLK1 is poor (FIG. 3), it is difficult to completely separate hyperglycosylated hKLK1 and hypoglycosylated hKLK1. For the recombinant hKLK1 after mutation, only one main peak needs to be collected during purification by hydrophobic chromatography, making the purification process easier.
[0088] The purity of the purified samples was analyzed by SDS-PAGE gel electrophoresis. The molecular weight of each mutant purified sample was confirmed to be very close to that of the unmutated, underglycosylated hKLK1. The results showed that hyperglycosylated hKLK1, which contains many sugar modifications at N141, was completely eliminated (Figure 6), and the proportion of hypoglycosylated hKLK1 was higher, resulting in higher yields and more homogeneous products.
[0089] The amino acid coverage of recombinant hKLK1 was measured and analyzed based on LC-MS. The coverage with the theoretical amino acid sequence was 100% (Figure 12), confirming the accuracy of the primary sequence of recombinant hKLK1. In addition, the glycosylation modification sites were identified, and the recombinant hKLK1 contained only two glycosylation modification sites (N78 and N84), which is consistent with the molecular design goal. Other mutants showed similar results.
[0090] [Table 10]
[0091] Example 4: Protein sample before and after mutation MS molecular weight measurement after deglycosylation treatment The molecular weights of the deglycosylated recombinant proteins before and after the mutation were measured by LC-MS. The recombinant proteins were denatured with guanidine hydrochloride, enzymatically digested with the sugar-cleaving enzyme PNGaseF, and then the molecular weights were measured. The molecular weight of the deglycosylated hyperglycosylated hKLK1 was 26380.338 Da, which is almost the same as the theoretical molecular weight of 26377.493 Da (Table 11). The molecular weight of the deglycosylated hypoglycosylated hKLK1 was 26379.346 Da, which is almost the same as the theoretical molecular weight of 26418.48 Da (Table 11). The molecular weight of the deglycosylated hKLK1X1 was 26418.82 Da, which is almost the same as the theoretical molecular weight of 26418.48 Da (Table 11). The molecular weights of hKLK1X2, hKLK1X3, and hKLK1X4 after deglycosylation were also almost consistent with the theoretical molecular weights. The above results further confirmed the accuracy of the primary structures of these recombinant proteins.
[0092] [Table 11]
[0093] Example 5 Preparation, purification and purity analysis of PEG-modified hKLK1 / hKLK1X samples The hKLK1 / hKLK1X samples modified with different PEGs can be prepared and purified by conventional methods, as exemplified in the present example below.
[0094] 1. Preparation of PEG-modified samples (1) Pretreatment The raw unmutated, underglycosylated recombinant hKLK1 protein was taken and treated with a 3 kDa ultrafiltration membrane (or other buffer replacement methods with equivalent effect), and the buffer was replaced with sodium dihydrogen phosphate / disodium hydrogen phosphate buffer at pH 7.0, and at the same time the protein concentration was concentrated to 15 mg / mL.
[0095] (2) Feed Modification Preparation of randomly modified PEG5K-hKLK1: M-SAP-PEG5K was added to the pretreated hKLK1 protein solution so that the mass ratio of hKLK1 protein to M-SAP-PEG5K was 1:25, and the mixture was stirred slowly to mix uniformly, and then allowed to react for 24 hours at 4°C.
[0096] Preparation of randomly modified PEG10K-hKLK1: M-SAP-PEG10K was added to the pretreated hKLK1 protein solution so that the mass ratio of hKLK1 protein to M-SAP-PEG10K was 1:20, and the mixture was stirred slowly to mix uniformly, and then allowed to react for 24 hours at 4°C.
[0097] Preparation of site-specifically modified PEG30K-hKLK1: Y-PALD-PEG30K was added to the pretreated hKLK1 protein solution so that the molar ratio of hKLK1 protein to Y-PALD-PEG30K was 1:6, and a reducing agent (sodium cyanoborohydride) was added to the mixed solution of PEG30K and protein so that the molar ratio of PEG to reducing agent was 1:50. The mixture was stirred slowly to mix uniformly, and then reacted at 4°C for 24 hours.
[0098] Preparation of site-specifically modified PEG40K-hKLK1: Y-PALD-PEG40K was added to the pretreated hKLK1 protein solution so that the molar ratio of hKLK1 protein to Y-PALD-PEG40K was 1:6, and a reducing agent (sodium cyanoborohydride) was added to the mixed solution of PEG40K and protein so that the molar ratio of PEG to reducing agent was 1:50. The mixture was stirred slowly to mix uniformly, and then reacted at 4°C for 24 hours.
[0099] II. Purification of the reaction mixture The chromatography conditions were as follows: The purification packing material is GE's Q Sepharose. TM High Performance medium was used, and the mobile phase Buffer A was 50 mM Tris-HCl 9 0, and Buffer B is 50 mM Tris-HCl + 1M NaCl 9.0 . Sample loading: After the reaction was completed, the PEG-hKLK1 modified reaction mixture was taken and diluted about 10 times with double distilled water, and then further diluted about 5 times with Buffer A. The sample was loaded and purified. After the sample loading was completed, the chromatography column was washed with Buffer A for more than 5 column bed volumes.
[0100] Elution: A 0-50% Buffer B gradient was set up to elute over 10 column bed volumes, and the eluted samples were collected stepwise based on the UV280 trend.
[0101] The PEG-modified hKLK1 mutant (PEG-hKLK1X) was prepared and purified according to the above method.
[0102] 3. Purity analysis of PEG-modified samples (1) Purity analysis by HPLC The measurement was performed with reference to the 2020 edition of the Chinese Pharmacopoeia, General Rule 0512, high performance liquid chromatography method. The type of measurement chromatography was SEC (size exclusion chromatography), the mobile phase was 20 mM PB pH 7.0 buffer containing 5% isopropanol, the chromatography column was BEH450 SEC 3.5 μm, the collection conditions were 280 nm, and the collection time was 20 to 25 minutes.
[0103] The results of the liquid phase assay showed that the PEG-hKLK1 / hKLK1X proteins The purity of the quality was all ≧95%.
[0104] (2) Purity analysis by SDS-PAGE The purity of the samples was determined according to the SDS-polyacrylamide gel electrophoresis method of the fifth method of electrophoresis 0541 in the 2020 edition of the Chinese Pharmacopoeia. was prepared and the samples were measured.
[0105] The electrophoretic results showed that the molecular bands of the prepared series of PEG-hKLK1 / hKLK1X proteins were uniform, no impurity bands were observed, and all had good purity.
[0106] (3) Measurement of the number of PEG bonds a) Preparation of solutions: PEG standard solutions of 1, 2, 4, 6 and 8 mg / mL were prepared, and recombinant hKLK1 and its PEG-modified solutions of 1 mg / mL were prepared. b)Measurement method: Chromatography column: XBridge BEH SEC 3.5μm 450A ;Column temperature: 25°C. Mobile phase: 20mM PB pH7.0+10%IPA, flow rate 0.4mL / min. Detector: PDA detector, detection wavelength 280 nm; RI detector, detection wavelength 280 nm.
[0107] c) Data analysis: Measured concentration of test sample (PEG modification) = Peak area of test sample (PEG modification) measured by PDA detector / Peak area of unmodified original protein measured by PDA detector × 1.0 PEG peak area in sample = (peak area of sample (PEG-modified) measured by RI detector / measured concentration of sample (PEG-modified)) - (peak area of unmodified original protein measured by RI detector / concentration of unmodified original protein)
[0108] The PEG concentration in the sample is calculated by substituting the PEG peak area in the sample into the PEG standard curve.
[0109] Number of PEG bonds in a sample = (PEG concentration in a sample / MW of PEG) / (sample Protein concentration / protein molecular weight 26kD)
[0110] [Table 12]
[0111] Example 6 In vitro activity measurement of recombinant human kallikrein 1 (hKLK1) and its mutant (hKLK1X) 1. In vitro activity evaluation using artificial substrates KLK1 exerts its biological function in vivo by catalyzing the hydrolysis of low molecular weight kininogen LMWK to release lysylbradykinin. The hydrolysis reaction involves the cleavage of the peptide bond at the carboxyl end of arginine (Arg). Therefore, it is possible to evaluate the in vitro biological activity of recombinant hKLK1 and its mutants through the detection of the production of paranitroaniline (PNA) at 405 nm based on the cleavage of the amide bond between Arg and paranitroaniline in the chromogenic artificial synthetic substrate S-2266 (H-D-Val-Leu-Arg-PNA). The activity unit IU is defined as the amount of enzyme that hydrolyzes 1 μmol of S-2266 to produce PNA in one minute under the conditions of 37°C and pH 8.0. The reaction system consists of 200 μl 20 mM trishydroxymethylaminomethane buffer, 10 μl of the test sample, and 20 μl 20 mM S-2266 substrate solution. The reaction system was incubated in a water bath at 37°C for exactly 10 min, and 20 μl of 50% acetic acid solution was added to stop the reaction. The amount of PNA produced in the reaction system was quantified by a standard curve fitted based on different concentrations of PNA standards. Using the above method, the in vitro biological activities of hyperglycosylated hKLK1, hypoglycosylated hKLK1, hKLK1 mutants, and hKLK1-PEG modified samples were measured.
[0112] The results are shown in the table below. The activity of the low glycosylated hKLK1 (unmutated) sample was significantly higher than that of the high glycosylated hKLK1 (unmutated) sample. A series of PEG-modified products of the unmutated protein showed higher in vitro activity than the randomly modified products and the site-specifically modified products, with the activity of PEG10K-hKLK1 (low glycosylation) being particularly superior. The activities of the site-mutated mutants (hKLK1X1, hKLK1X2, hKLK1X3, hKLK1X4) were all higher than that of the low glycosylated unmutated hKLK1 sample. The activity of the PEG-modified samples was slightly lower than that of the unmodified hKLK1X1 protein, while the activity of PEG10K-hKLK1X1 was higher than that of PEG5K-hKLK1X1, and the protein after PEG10K modification mostly retained the activity of the original protein.
[0113] [Table 13]
[0114] 2. In vitro activity measurement using natural substrates 1. Enzyme reaction and liquid phase measurement KLK1 catalyzes the hydrolysis of low molecular weight kininogen LMWK in vivo, liberating lysylbradykinin to exert its biological function. In this example, the substrate (low molecular weight kininogen LMWK) and enzyme (KLK1 or its PEG-modified form) are reacted at different ratios to compare the production status of the effector molecule bradykinin. The effector molecules produced are separated by reversed-phase chromatography, the peak area of the product is calculated, and the curves of the production status of bradykinin when the substrate and enzyme react at different ratios are drawn, and the amount of effector molecules produced by different test samples under the same reaction conditions are compared. In this way, the action mode in the body is simulated in vitro, and the effects of different test sample samples on the body are indirectly compared.
[0115] The hKLK1X1 in the test sample was prepared by the method described in Example 3, PEG10K-hKLK1X1 was prepared by the method described in Example 5, Kb was KLK1 extracted from pig pancreas, and PEG-Kb was an injectable pancreatic kallikrein 1 which is a PEG10K-modified Kb, and was prepared with reference to Example 5.
[0116] The samples were mixed and reacted according to the table below (in the case of PEG-modified samples, the molar mass of the active substance to be modified was used as the conversion factor). The mixed samples were placed in a 37°C incubator and incubated for 15 minutes while keeping an accurate time, and the reaction was stopped by adding 50% acetic acid solution at a volume ratio of 10:1.
[0117] [Table 14]
[0118] After the reaction was stopped, the samples were placed in a tabletop centrifuge and centrifuged at 12000 rpm for 5 minutes, and the supernatant was taken. Waters ACQUITY UPLC H-Class measurement was performed, with mobile phase A being 0.1% TFA-H2O, mobile phase B being 0.1% TFA-ACN, the measurement wavelength being 214 nm, the column temperature being 30°C, the sample loading volume was all 10 μl, the flow rate was 0.2 mL / min, the run time was 35 minutes, and the run gradient was as follows:
[0119] [Table 15]
[0120] 2, results Based on the results of the UPLC chromatogram of the enzyme reaction mixture, the peak with a retention time of 13±0.5 min (peak position of bradykinin) on the chromatogram of the reaction mixture was integrated to obtain the sum, and the concentration of bradykinin produced in the enzyme reaction was calculated by comparing with the peak area of bradykinin per unit mass (1 mg / mL, 10 μL sample loading amount). The amount of bradykinin produced was calculated based on the total reaction system in Table 14, and finally converted to the amount of bradykinin produced per 1 mg enzyme (μg / mg) under each molar ratio condition. The results are shown in Table 16.
[0121] [Table 16]
[0122] The results of the measurements using natural substrates showed that the overall tendency was that the amount of bradykinin produced by the enzymatic reaction was lower in the modified protein than in the unmodified sample. This is consistent with the consistent properties of PEG-modified proteins. Taken together with the data in Examples 9-13, it is believed that the PEG-modified protein can maintain a gentler enzymatic reaction than the original protein, enabling the sustained production of effector molecules. In addition, KLK1 The effects of these drugs are based on the regulation of the kallikrein-kinin system (KKS) in the body, which involves the production and elimination of effector molecules. Therefore, the gentle and sustained enzyme reaction process can effectively reduce the elimination mechanism in the KKS, allowing the drugs provided by the present invention to exert their biological effects more stably and effectively.
[0123] Furthermore, when Kb was compared with hKLK1X1 and its modified products, the sample provided by the present invention produced a higher amount of effector molecules. This is consistent with the results of the in vivo efficacy experiments using animals shown in Examples 10-13. These experiments demonstrate that the hKLK1X1 protein provided by the present invention has a significant advantage over animal-derived KLK1.
[0124] Example 7 In vitro enzyme kinetics measurement for PEG-modified hKLK1 / hKLK1X etc. 1.Measurement method (1) Dilution of standard: The standard pancreatic kallikrein 1 (provided by Changzhou Qianhong Chemical Pharmaceutical) was diluted to 10 IU / mL using S2266 substrate buffer (20 mM Tris-HCl 8.5). The diluted standard was diluted to 1, 2, 3, 4, 5, and 6 IU / mL according to the table below to prepare standard curve samples.
[0125] [Table 17]
[0126] (2) Preparation of substrates with different concentrations: The already dispensed substrate S2266 was diluted with the S2266 substrate buffer to prepare substrate solutions of 400, 200, 100, 50, 25, and 10 μM, respectively.
[0127] (3) Sample dilution: Samples were diluted to 1-6 IU / mL using S2266 substrate buffer.
[0128] (4) Adding samples: The standard curve samples prepared in (1) above were added to a microplate at 80 μL / well, one well per sample. The diluted samples in (3) above were added to a microplate at 80 μL / well, six wells per sample in parallel.
[0129] (5) Reading: The microplate reader was set to perform kinetic measurements at 37°C and 405 nm, with a reading interval of 1 min and a measurement time of 15 min. Substrate was added when the temperature of the instrument sample pool rose to 37°C, with 80 μL / well of 200 μM substrate added to the standard curve samples, and 80 μL / well of different concentrations of substrate prepared in (2) added to the six parallel wells of the samples to be measured. Care should be taken to add the samples quickly and blow to mix evenly. After the sample addition, readings were started immediately and then taken every minute.
[0130] (6) Results processing: The results were processed using the software GraphPad Prism, and the data were fitted based on the Michaelis-Menten equation to calculate the enzyme kinetic parameters. Here, K m is the Michaelis-Menten constant, and the maximum enzyme reaction velocity (V max ) is the substrate concentration that gives half the rate of the reaction. m The affinity of an enzyme for its substrate is approximately expressed as 1 / K m The larger the value, the greater the enzyme's affinity for its substrate. This allows the enzyme reaction to proceed easily.
[0131] II. Experimental Results The results of the enzyme kinetic measurements for each sample are shown in the table below.
[0132] [Table 18]
[0133] Enzyme kinetic measurements showed that hKLK1X1 has a higher K m The K values were lower, indicating that the affinity for the substrate was improved after the mutation. In addition, the K values of the two mutant PEG-modified forms were lower than those of the unmutated PEG-modified form. m The values were lower, indicating that the two modifications of the mutant protein had better performance in enzymatic properties than the modifications of the unmutated protein.
[0134] Example 8 In vivo pharmacokinetic comparison of PEG-modified hKLK1 in rats 1. Grouping Based on the body weight of SD rats measured on the first day of the experiment, the rats were randomly divided into six groups according to body weight: PEG5K-hKLK1 (high glycosylation) intravenous injection group (0.5 mg / kg), PEG5K-hKLK1 (high glycosylation) subcutaneous injection group (0.5 mg / kg), PEG10K-hKLK1 (low glycosylation) intravenous injection group (0.5 mg / kg), PEG10K-hKLK1 (low glycosylation) subcutaneous injection group (0.5 mg / kg), PEG10K-hKLK1X1 intramuscular injection group (0.1 mg / kg), and PEG10K-hKLK1X1 intramuscular injection group (0.02 mg / kg). There were six rats in each group, half female and half male. The animals were stained and numbered. A single dose was administered on the first day of the experiment.
[0135] 2. Collecting blood samples and preparing samples for testing Measurement times: Blood was collected once each at 0 min (before administration), 30 min, 1 h, 2 h, 4 h, 8 h, 24 h, 2 d, 3 d, 5 d, and 7 d, for a total of 11 blood samples.
[0136] Blood collection volume: 50-100 μL of serum was collected and used for the measurement of pharmacokinetic parameters.
[0137] Sample preparation 1) Pharmacokinetic sample: The sample was diluted to a quantification limit concentration range of 2560 ng / mL to 80 ng / mL using 10% SD rat mixed blank serum (SD rat mixed blank serum: blocking solution (2% BSA in PBST) = 1:9).
[0138] 2) Standard: Using SD rat mixed blank serum, dilute the PEG-modified products of high-glycosylated hKLK1 and low-glycosylated hKLK1 to obtain a concentration gradient range of 5120 ng / mL to 5120 ng / mL. A 2-fold dilution series of standards at 40 ng / mL was prepared.
[0139] 3) Controls: Using SD rat mixed blank serum, PEG-modified products of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 were diluted to prepare high (1920 ng / mL), medium (480 ng / mL), and low (240 ng / mL) concentration controls.
[0140] 3. Pharmacokinetic measurements The drug concentration in serum was measured by ELISA. The analytical process is as follows: 1) Coating: Anti-hKLK1 antibody was diluted to 400ng / well with 20mM phosphate buffer (PB, pH7.4) and coated. The diluted and coated antibody was sucked up and added to the wells of a microplate (100uL / well), the plate was sealed, and coated overnight at 4℃. The coating plate was a Thermo microplate.
[0141] 2) Blocking: Discard the liquid in the wells, wash the plate once with a microplate washer, and shake to dry. Add 200uL / well of blocking solution (20mM PBS containing 2% BSA and 0.05% Tween20), seal the plate, and incubate at 37℃ for approximately 2 hours.
[0142] 3) Add samples: Remove the liquid from the wells, dilute the pharmacokinetic samples to be measured, the standards, and the control solutions 10-fold with blocking solution, and then add 100uL / well to the microplate. Seal the plate and incubate at 37℃ for approximately 1.5 hours. did.
[0143] 4) Add detection antibody: Discard the liquid in the wells, wash the plate three times with a microplate washer, add 300uL / well, shake and dry. Add detection antibody working solution (dilute detection enzyme-labeled anti-hKLK1 antibody to 1ug / mL with blocking solution) at 100uL / well, seal the plate, and incubate at 37℃ for about 45 minutes.
[0144] 5) Color development: Discard the liquid in the wells, wash the plate 5 times with a microplate washer, shake and dry with 300uL / well, add TMB color development solution No. 1, and incubate at 37℃ for 15 minutes (depending on the color development).
[0145] 6) Plate reading: Stop solution (2M H2SO4) was added at 50uL / well to stop the reaction, and the OD value at 450nm was immediately measured. A standard curve was drawn with the concentration of the standard curve sample on the X-axis and the OD value on the Y-axis, and the sample concentration was calculated.
[0146] 7) The standard curve was drawn using Origin8 software, and sample concentrations were calculated. Mean values, standard deviations, and coefficients of variation were calculated using Microsoft EXCEL. AUC (area under the curve) was calculated using GraphPad Prism7.00.
[0147] 4. Measurement results At equivalent doses, the in vivo drug exposure (AUC) is as follows:
[0148] [Table 19]
[0149] The above pharmacokinetic results showed that PEG10K-hKLK1 (low glycosylation) showed significantly better pharmacokinetic curves and longer drug half-life than PEG5K-hKLK1 (high glycosylation) both in intravenous and subcutaneous injections. PEG10K-hKLK1X1 showed good absorption even at low doses in intramuscular injections.
[0150] Example 9 Comparison of in vivo immunogenicity in rats between PEG-modified products of hyperglycosylated hKLK1 and hypoglycosylated hKLK1 1. Grouping Based on the body weight of SD rats measured on the first day of the experiment, the rats were randomly divided into two groups according to body weight: PEG5K-hKLK1 (high glycosylation) group and PEG10K-hKLK1 (low glycosylation) group. There were 12 rats in each group, half female and half male. The animals were stained and numbered.
[0151] Second, administration Route of administration: intravenous injection. Dosage frequency: Administer once weekly for 8 doses. Dosage: Each group will be administered at a dose of 0.5 mg / kg with a dosing concentration of 0.2 mg / mL.
[0152] 3. Collecting blood samples Measurement time: Blood was collected once each at 0 min (before administration), 3 days after administration, and 7 days after administration. Blood was collected once a week during the recovery period. The recovery period lasted for 2 weeks. Approximately 500 μL of whole blood was collected each time, left to stand for 2 hours, and centrifuged at 3000 rpm for 10 minutes. The separated serum was used to measure immunogenicity.
[0153] IV. Immunogenicity measurement 1) Coating: The working solution of the coating antigen (PEG-modified hKLK1) was added to the microwells at 100 μL / well and incubated overnight at 2-8°C. 2) Blocking: Discard the liquid in the wells, wash the plate three times, shake and dry it. Blocking solution (20 mM PBS containing 2% BSA and 0.05% Tween 20) was added. 200 uL / well was added and incubated at 37° C. for approximately 2 hours. 3) Sample treatment: All animal serum samples were diluted 10-fold with blocking solution. 4) Adding the sample: Discard the liquid in the microplate wells and shake to dry. Add 100 μL of treated sample to each well and incubate at 37°C, 200 rpm for about 2 hours with shaking.
[0154] 5) Adding the detection antigen working solution: The liquid in the microplate wells was discarded, and the plate was washed three times and shaken to dry. 100uL / well of the detection antigen working solution (biotin-labeled PEG-modified hKLK1 was diluted to 2.5μg / mL with the blocking solution to prepare the detection antigen working solution) was added to each well of the screening microplate, and 100uL / well of the confirmation assay detection antigen working solution (PEG-modified hKLK1 was diluted to 200μg / mL with the detection antigen working solution as the diluent to prepare the confirmation assay detection antigen working solution) was added to each well of the confirmation microplate, and the mixture was incubated at 37℃ and 200rpm with shaking for about 1 hour.
[0155] 6) Add signal amplification detector working solution (streptavidin-horseradish peroxidase diluted to 0.05 μg / mL in blocking solution): discard the liquid in the microplate wells, wash the plate three times, shake to dry, add 100 μl / well of signal amplification detector working solution, and incubate with shaking at 37°C, 200 rpm for approximately 1 hour.
[0156] 7) Color development: The liquid in the wells was discarded, the plate was washed three times, and then shaken and dried. 100 uL of color development solution was added to each well, and the plate was left at 37°C for 15 minutes in the dark.
[0157] 8) Stopping: The reaction was stopped by adding a stopping solution (2M H2SO4) at 100 μl / well, and the OD value at 450 nm was immediately measured using a microplate reader.
[0158] 5. Measurement results The immunogenicity evaluation results in Figures 13 and 14 show that no serum anti-drug antibodies (ADA) were detected in any of the 12 animals in the PEG-hKLK1 (low glycosylation) group, while relatively high ADA levels were detected in two animals in the 12 animals in the PEG-hKLK1 (high glycosylation) group, indicating that the immunogenicity of the low glycosylated protein modification is lower.
[0159] Example 10 Comparison of in vivo activity between injectable urinary kallikrein and injectable pancreatic kallikrein 1 1. Creating a model SD rats, male, SPD grade, weighing 270-300g, were used. A middle cerebral artery occlusion (MCAO) cerebral ischemia-reperfusion model was created using the middle cerebral artery embolization method. The animals were anesthetized with isoflurane, fixed in a supine position, the skin was disinfected, the midline of the neck was incised, the right common carotid artery, external carotid artery, and internal carotid artery were isolated, the vagus nerve was gently dissected, and the external carotid artery was ligated and cut. The proximal end of the carotid artery was clamped, an incision was made distal to the ligated part of the external carotid artery, and an MCAO wire plug (model number 2438-A5, purchased from Beijing Seino Technology Co., Ltd.) was inserted, passed through the common carotid artery bifurcation and entered the internal carotid artery, and gradually inserted until a slight resistance was felt (approximately 20 mm from the bifurcation), blocking the blood flow of the middle cerebral artery. The neck skin was sutured, disinfected, and the rat was returned to its cage. After 90 minutes of ischemia, the rat was anesthetized again, fixed to a board, the neck skin was incised, the thrombus was located and gently removed, and blood flow was restored to allow reperfusion. The neck skin was sutured, disinfected, and the rat was returned to its cage for rearing.
[0160] Grouping: 4 groups in total, namely, sham operation group, model group, and injectable pancreatic kallikrein group (0.4 IU The administration group was administered 2 hours after reperfusion. The specific activity of all samples used in the animal experiments was calculated by the method shown in Example 6. The injectable pancreatic kallikrein 1 was a PEG10K-modified Kb, which was produced by the method described in Example 5. Kb was KLK1 extracted from the pancreas of a pig.
[0161] 2. Evaluation of neurological deficit symptoms Neurological deficit symptoms are assessed using a modified Bederson 5-point scale.
[0162] [Table 20]
[0163] 3. Measurement of cerebral infarction volume The animals were anesthetized with 10% chloral hydrate, and the head was cut and the brain was removed. The olfactory bulb, cerebellum, and lower brain stem were removed, and blood stains on the surface of the cerebrum were washed off with saline, and the residual moisture on the surface was blotted and left at -80°C for 7 minutes. After that, immediately after removal, a coronal section was cut downward perpendicular to the cross plane of the line of sight, and further sections were cut posteriorly every 2 mm. The brain sections were placed in a TTC (20 g / L) staining solution freshly prepared with saline and warmed at 37°C for 90 minutes, and normal brain tissue was stained deep red and ischemic brain tissue was pale. After rinsing with saline, the brain sections were immediately arranged in order from front to back, the residual moisture on the surface was blotted, and photographed. Statistics were taken based on the photographs using image analysis software (Image Tool), and the right ischemic area (white area) and the right area were surrounded to calculate the percentage of cerebral infarction area using the following formula. Calculation formula: cerebral infarction area% = total ischemic area ÷ total right area × 100.
[0164] 4. Results 1. Effect of the test substance on symptoms of neurological disorders As shown in FIG. 15 and Table 19, the urinary kallikrein group (F 7,87 = 20.80, P = 0.018) was significantly lower in the neuropathy symptoms compared with the model group. In addition, the pancreatic kallikrein injection group 1 (F 7,87 = 20.80, P = 0.021) had a significant improvement effect on neurological symptoms compared with the model group.
[0165] [Table 21]
[0166] 2. Effect of the test substance on cerebral infarction area (%) As shown in Figures 16, 17, and 18 and Table 20, the urinary kallikrein group (F 7,87 = 12.72, P = 0.042), and injectable pancreatic kallikrein 1 group (F7,87 = 12.72, P = 0.019) had a significant improving effect on cerebral infarction size compared to the model group.
[0167] [Table 22]
[0168] 3. Effect of test substance on cumulative mortality rate (%) As shown in Table 21, all groups except the sham-operated group experienced animal deaths, but there was no difference in mortality between the groups. 1,28 = 0.18, P = 0.6746), injectable kallikrein 1 group (F 1,28 = 0.18, P = 0.6753) was not statistically significantly different from the model group.
[0169] [Table 23]
[0170] 4, Conclusion When the test substance was administered as a treatment after ischemia-reperfusion, the test substance Urinalysis Both ry Kallikrein and injectable pancreatic kallikrein 1 had significant brain protective effects.
[0171] Example 11 In vivo activity evaluation of unmutated hyperglycosylated hKLK1 modified with PEG10K The methods for preparing the model, evaluating the symptoms of neurological deficit, and measuring the cerebral infarction volume were the same as those in Example 10. Grouping and medication: A total of four groups were set up: sham operation group, model group, positive drug group (injectable pancreatic kallikrein 1, 0.4 IU / kg, intramuscular injection), and PEG10K-hKLK1 (highly glycosylated) group (0.1 IU / kg, intravenous injection). The treatment group was administered medication 2 hours after reperfusion.
[0172] 2. Results 1. Effect of the test substance on neurological deficit symptoms As shown in FIG. 19 and Table 22, the test substance PEG10K-hKLK1 (high glycosylation) group (F 3,43 = 63.32, P = 0.352) had a certain improvement effect on neurological deficit symptoms compared to the model group, but the difference was not statistically significant. 3,44 = 56.34, P = 0.006) had a significant improvement effect on neurological deficit symptoms compared with the model group.
[0173] [Table 24]
[0174] 2. Effect of the test substance on cerebral infarction area (%) As shown in Figures 20, 21, 22 and Table 23, the PEG10K-hKLK1 (hyperglycosylation) group (F 3,43 = 37.72, P = 0.197) showed a certain improvement effect on cerebral infarction size compared to the model group, but the difference was not significant. 3,44 = 34.58, P = 0.007) had a significant improvement effect on cerebral infarction size compared to the model group.
[0175] [Table 25]
[0176] 3. Effect of test substance on cumulative mortality rate (%) As shown in Table 24, all groups except the sham operation group experienced animal deaths, but there was no difference in mortality between groups. 1,6 = 0.00, P = 1.0000), PEG10K‐hKLK1 (high glycosylation) group (F 1,6 = 0.00, P = 1.0000) was not statistically significantly different from the model group.
[0177] [Table 26]
[0178] 4, Conclusion When the test product was administered as treatment after ischemia-reperfusion, the test product PEG10K-hKLK1 (hyperglycosylated) showed a tendency to improve symptoms compared to the model group, but the difference was not statistically significant.
[0179] Example 12 In vivo activity evaluation of native underglycosylated hKLK1 modified with different PEGs 1. The methods for preparing the model, evaluating the symptoms of neurological deficit, and measuring the volume of cerebral infarction were the same as those in Example 10. Grouping and medication: A total of seven groups were established, namely, sham operation group, model group, positive drug group (injectable pancreatic kallikrein 1, 0.4 IU / kg, intramuscular injection), PEG40K-hKLK1 (low glycosylation) group (0.1 IU / kg), PEG30K-hKLK1 (low glycosylation) group (0.1 IU / kg), PEG10K-hKLK1 (low glycosylation) group (0.1 IU / kg), and PEG5K-hKLK1 (low glycosylation) group (0.1 IU / kg). The administration group was administered 2 hours after reperfusion. The dosage of each administration group was calculated based on the specific activity of the sample, and the same activity unit of PEG-hKLK1 modification was administered per kilogram body weight.
[0180] 2. Results 1. Effect of the test substance on neurological deficit symptoms As shown in FIG. 23 and Table 25, the PEG40K-hKLK1 (low glycosylation) group (F 3,44 = 46.28, P = 0.209), PEG30K‐hKLK1 (low glycosylation) group (F 3,43 = 53.33, P = 0.242), PEG5K‐hKLK1 (low glycosylation) group (F 3,44 = 46.28, P = 0.209) showed a certain improvement effect on neurological deficit symptoms compared to the model group, but the difference was not statistically significant. On the other hand, the PEG10K-hKLK1 (low glycosylation) group (F 3,45 =46.43, P=0.008), positive drug group (F 3,45 = 46.43, P = 0.003) had a significant improvement effect on neurological deficit symptoms compared with the model group.
[0181] [Table 27]
[0182] 2. Effect of the test substance on cerebral infarction area (%) As shown in Figures 24, 25, 26 and Table 26, the PEG40K-hKLK1 (low glycosylation) group (F 3,44 = 37.73, P = 0.446), PEG30K‐hKLK1 (low glycosylation) group (F 3,43 = 36.56, P = 0.502), PEG5K‐hKLK1 (low glycosylation) group (F 3,44 = 39.05, P = 0.218) showed a certain improvement effect on cerebral infarction size compared to the model group, but the difference was not significant. 3,45 =39.30, P=0.001), positive drug group (F 3,45 = 39.30, P = 0.001) had a significant improvement effect on cerebral infarction size compared to the model group.
[0183] [Table 28]
[0184] 3. Effect of test substance on cumulative mortality rate (%) As shown in Table 27, all groups except the sham operation group experienced animal deaths, but there was no difference in mortality between groups. 1,3 = 0.15, P = 0.7239), PEG40K‐hKLK1 (low glycosylation) group (F 1,3 = 0.17, P = 0.7100), PEG30K‐hKLK1 (low glycosylation) group (F 1,3 = 0.17, P = 0.7106), PEG10K‐hKLK1 (low glycosylation) group (F 1,3 = 0.15, P = 0.7239), PEG5K‐hKLK1 (low glycosylation) group (F 1,3 = 0.00, P = 0.9994) was not statistically significantly different from the model group.
[0185] [Table 29]
[0186] 4, Conclusion According to the results of this example, among the unmutated hypoglycosylated hKLK1, PEG10K-hKLK1 (hypoglycosylation) showed a significant brain protective effect in the in vivo animal model, and PEG5K-hKLK1 (hypoglycosylation), PEG40K-hKLK1 (hypoglycosylation), and PEG30K-hKLK1 (hypoglycosylation) also showed a tendency to improve symptoms. Furthermore, the results of the efficacy experiments conducted in vivo and in vitro showed a certain correlation, and the in vitro activity of PEG10K-modified hypoglycosylated hKLK1 was higher than that of PEG5K-modified hypoglycosylated hKLK1 and higher than that of PEG30K / 40K-modified hypoglycosylated hKLK1.
[0187] Overall, the results of Examples 11 and 12 show that the efficacy of the PEG10K-hKLK1 (high glycosylation) sample is inferior to that of the PEG10K-hKLK1 (low glycosylation) sample when evaluated at the same dose. This suggests that the efficacy of the unmodified low glycosylated sample is superior to that of the high glycosylated sample when the same PEG modification is applied.
[0188] Example 13 In vivo activity evaluation of different PEG-modified hKLK1 mutants 1. The methods for preparing the model, evaluating the symptoms of neurological deficit, and measuring the volume of cerebral infarction were the same as those in Example 10. Grouping: A total of four groups were established, namely, sham operation group, model group, PEG5K-hKLK1X1 group (0.1 IU / kg), and PEG10K-hKLK1X1 group (0.1 IU / kg). The treatment group was administered intravenously 2 hours after reperfusion.
[0189] 2. Results 1. Effect of the test substance on neurological deficit symptoms As shown in FIG. 27 and Table 28, the PEG5K-hKLK1X1 group (F 2,38= 67.13, P = 0.017) showed a significant improvement in neurological deficit symptoms compared to the model group. 2,37 = 86.65, P = 0.003) had a significantly improved effect on neurological deficit symptoms compared with the model group.
[0190] [Table 30]
[0191] 2. Effect of the test substance on cerebral infarction area (%) As shown in Figures 28, 29, and 30 and Table 29, the PEG5K-hKLK1X1 group (F 2,38 =39.50, P=0.001), PEG10K-hKLK1 group (F 2,37 = 90.5, P = 0.000) had a significant improvement effect on cerebral infarction size compared to the model group.
[0192] [Table 31]
[0193] 3. Effect of test substance on cumulative mortality rate (%) As shown in Table 30, all groups except the sham-operated group experienced animal deaths, but there was no difference in mortality between groups. 1,5 = 0.71, P = 0.4369), and the PEG10K‐hKLK1X1 group (F1,5 = 0.00, P = 1.0000) were not statistically different from the model group.
[0194] [Table 32]
[0195] 4, Conclusion When the test substances were administered in the treatment after ischemia-reperfusion, compared with the model group, both test substances PEG5K-hKLK1X1 and PEG10K-hKLK1X1 had a significant brain protection effect. Taking into account Examples 12 and 13 as a whole, the in vivo efficacy of PEG-hKLK1 (unmutated) / hKLK1X (mutant) is summarized in Table 31.
[0196] [Table 33]
[0197] In other words, when modified with the same PEG modifier, the hKLK1 protein mutated at the N141 site is significantly more effective as a drug molecule than the unmutated version, and the mutated protein shows improved performance and better in vivo therapeutic effects.
[0198] The drugs that showed in vivo efficacy in Examples 10 to 13 are summarized in Table 32.
[0199] [Table 34]
[0200] That is, when modified with the same modifying agent, unmutated underglycosylated hKLK1 has a superior therapeutic effect compared to unmutated overglycosylated hKLK1, and NFS-mutated hKLK1 protein has a superior therapeutic effect compared to unmutated underglycosylated hKLK1, and has a significantly superior therapeutic effect even at a lower dose.
[0201] Example 14: Efficacy study of PEG-hKLK1 via different administration routes 1. The methods for preparing the model, evaluating the symptoms of neurological deficit, and measuring the volume of cerebral infarction were the same as those in Example 10. Grouping: Three groups were set up in total, namely, sham operation group, model group, and PEG10K-hKLK1X1 intramuscular injection group (0.4 IU / kg). The treatment group was administered the drug 2 hours after reperfusion.
[0202] 2. Results 1. Effect of the test substance on neurological deficit symptoms As shown in FIG. 31 and Table 33, the PEG10K-hKLK1X1 intramuscular injection group (F 2,36 = 122.84, P = 0.000) had a significantly improved effect on neurological deficit symptoms compared with the model group.
[0203] [Table 35]
[0204] 2. Effect of test substance on cerebral infarction area (%) As shown in FIG. 32 and Table 34, the PEG10K-hKLK1X1 intramuscular injection group (F 2,36 = 55.02, P = 0.001) had a significantly more significant improving effect on cerebral infarction size compared to the model group.
[0205] [Table 36]
[0206] 4, Conclusion Overall, in Example 13 and Example 14, PEG10K-hKLK1X1 has a very significant brain protection effect when administered by two routes, i.e., intravenous injection (0.1 IU / kg) and intramuscular injection (0.4 IU / kg). It has also been confirmed that it can effectively treat the neurological deficit symptoms after stroke in animals and significantly improve the cerebral infarction area.
[0207] In summary, compared with hyperglycosylated KLK1, the hypoglycosylated KLK1 of the present invention has higher activity, and compared with unmutated KLK1, the recombinant KLK1 mutant has one less N-glycosylation modification site, which makes the purification process simpler, improves the uniformity of the product, facilitates quality control, and increases the production volume. And, compared with unmutated hypoglycosylated KLK1, the KLK1 mutant of the present invention has further advantages in terms of enzymatic properties, activity, etc. Furthermore, the PEGylated recombinant hKLK1 of the present invention has been administered by various administration methods and all of them have shown remarkable efficacy. And, it has the advantages of safety and long-lasting action of polyethylene glycol drugs, which can reduce the administration frequency and improve patient compliance, and the application of the drug of the present invention in the entire disease process covering the stages of prevention, treatment, prognosis recovery, recurrence prevention, etc. of diseases such as acute ischemic stroke, peripheral neuropathy, retinal disease, ocular fundus disease, hypertension, diabetic nephropathy, IgA nephritis, chronic kidney disease, etc.
Claims
1. A hypoglycosylated modified kallikrein 1 or a derivative thereof, wherein the kallikrein 1 is a primate kallikrein 1 and contains N-glycosylation modifications at the NMS, NHT, and NFS sequences of native kallikrein 1, and is characterized in that the asparagine in NFS has no glycosylation modification or only a small amount of glycosylation modification, and the small amount of glycosylation modification or hypoglycosylation modification is such that the percentage of asparagine in NFS that is glycosylated is ≦10%, ≦9%, ≦8%, ≦7%, ≦6%, ≦5%, ≦4%, ≦3%, ≦2%, ≦1%, ≦0.5%, or ≦0.1%.
2. A recombinant kallikrein 1 mutant or a derivative thereof, wherein the kallikrein 1 is a primate kallikrein 1 and is a hypoglycosylated modified kallikrein 1 or a derivative thereof, characterized in that it has N-glycosylation modifications at only two sites.
3. The recombinant kallikrein 1 mutant or its derivative as described in claim 2 is characterized in that it retains the N-glycosylation modifications at NMS and NHT in the amino acid sequence of native kallikrein 1, and does not contain the N-glycosylation modification at NFS of native kallikrein 1.
4. The recombinant kallikrein 1 mutant or its derivative according to claim 2, characterized in that the asparagine of NFS in the amino acid sequence of the kallikrein 1 is mutated to any amino acid other than asparagine, and 0, 1, or 2 amino acids of F and S of NFS are mutated to any other amino acid.
5. The recombinant kallikrein 1 mutant or its derivative as described in claim 2, characterized in that the phenylalanine of NFS in the amino acid sequence of the kallikrein 1 is mutated to proline, and 0, 1, or 2 amino acids of N and S of NFS are mutated to any other amino acid.
6. The recombinant kallikrein 1 mutant or its derivative as described in claim 2, characterized in that the serine of NFS in the amino acid sequence of the kallikrein 1 is mutated to any amino acid other than serine or threonine, and 0, 1, or 2 amino acids of N and F of NFS are mutated to any other amino acid.
7. The recombinant kallikrein 1 mutant or its derivative according to claim 4, characterized in that the asparagine of NFS in the amino acid sequence of kallikrein 1 is mutated to a polar neutral amino acid, an acidic amino acid, a basic amino acid, or an aliphatic amino acid.
8. The recombinant kallikrein 1 mutant or its derivative according to claim 7, characterized in that the asparagine of NFS in the amino acid sequence of kallikrein 1 is mutated to glutamine (Gln), aspartic acid (Asp), arginine (Arg), or alanine (Ala).
9. 9. The recombinant kallikrein 1 mutant or derivative thereof according to any one of claims 2 to 8, wherein said kallikrein 1 is human kallikrein 1 and comprises asparagine of NFS, The recombinant kallikrein 1 mutant or a derivative thereof is characterized in that phenylalanine and serine are the amino acids at positions 141, 142, and 143 of human kallikrein 1, respectively, and the amino acid sequence of native human kallikrein 1 is a sequence registered under GenBank registration numbers AAA59455.1, NP002248.1, AAA36136.1, AAP35917, and AAU12569.
10. A recombinant kallikrein 1 mutant or derivative thereof according to any one of claims 2 to 8, wherein the amino acid sequence of said mutant is SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, S No. 4, SEQ ID No. 5 or SEQ ID No. 6, or a derivative thereof.
11. A composition comprising the kallikrein 1 or a derivative thereof according to claim 1, or a recombinant kallikrein 1 mutant or a derivative thereof according to any one of claims 2 to 10.
12. Use of the kallikrein 1 or a derivative thereof described in claim 1, or a recombinant kallikrein 1 mutant or a derivative thereof described in any one of claims 2 to 10, in the manufacture of a drug used for the treatment, prevention, prognosis improvement, and recurrence prevention of acute ischemic stroke, peripheral neuropathy, retinopathy, ocular fundus disease, hypertension, diabetic nephropathy, IgA nephritis, and chronic kidney disease.
13. The present invention relates to a polyethylene glycol-modified kallikrein 1, characterized in that the kallikrein 1 is modified with a polyethylene glycol modifying agent, and is a kallikrein 1 described in claim 1 or a recombinant kallikrein 1 mutant described in any one of claims 2 to 10.
14. The polyethylene glycol-modified kallikrein 1 according to claim 13, characterized in that the polyethylene glycol modifying agent is a linear polyethylene glycol succinimide propionate having a molecular weight of 5 kDa to 10 kDa and has a general structural formula as shown in formula (1), in which n is an integer of 105 to 225. 【Chemistry 1】 (1)
15. The polyethylene glycol-modified kallikrein 1 according to claim 13, characterized in that the polyethylene glycol modifying agent is a branched polyethylene glycol propionaldehyde having a molecular weight of 30 kDa to 40 kDa, and has a general structural formula as shown in formula (2), in which n is an integer of 335 to 455. 【Chemistry 2】 (2)
16. A composition comprising the pegylated kallikrein 1 described in any one of claims 13 to 15.
17. Use of the polyethylene glycolated kallikrein 1 according to any one of claims 13 to 15 in the manufacture of a drug used for the treatment, prevention, prognosis improvement, and recurrence prevention of acute ischemic stroke, peripheral neuropathy, retinopathy, ocular fundus disease, hypertension, diabetic nephropathy, IgA nephritis, and chronic kidney disease.
Citation Information
Patent Citations
PEG-modified medicinal kininogenase and preparation method and application thereof
CN107760661A
Human tissue kallikrein 1 glycosylation isoforms
US20130323222A1
Using methanol yeast to produce human kallikrein - 1
CN101092598A
Human urine kininogenase and method for making same
CN101134952A
Recombinant human pancreas kininogenase
CN101134953A
